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of a treatment  regime. There is currently 
no generally accepted way to predict 
treatment efficacy in individual patients, 
so medications are prescribed according 
to consensus recommendations. First-
line treatment is typically methotrexate 
(MTX), an inhibitor of protein and nu-
cleic acid synthesis that leads to inhibi-
tion of immune cells (1). Around 30% 
of RA patients do not respond to MTX 
and are then prescribed a combination 
of MTX and an anti-TNF blocking agent. 
TNF drives the inflammation within the 
joint, and blocking reduces immune cell 
infiltration and immune mediated joint 
destruction (2). About 30% of patients 
prescribed their first anti-TNF therapy 
with RA are often in working age and 
the accompanying fatigue significantly 
affects working capacity. Ongoing joint 
destruction is however seen in more 
than a third of patients after initiation 
InTroDUCTIon
Rheumatoid arthritis (RA) is a chronic 
inflammatory disease resulting pri-
marily in chronic inflammation and 
destruction of symmetric joints. Persons 
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OBJECTIVE: In rheumatoid arthritis (RA) several recent efforts have sought to discover means of predicting which patients 
would benefit from treatment. However, results have been discrepant with few successful replications. Our objective was to 
build a biobank with DNA, RNA and protein measurements to test the claim that the current state-of-the-art precision medi-
cine will benefit RA patients. METHODS: We collected 451 blood samples from 61 healthy individuals and 185 RA patients initi-
ating treatment, before treatment initiation and at a 3 month follow-up time. All samples were subjected to high-throughput 
RNA sequencing, DNA genotyping, extensive proteomics and flow cytometry measurements, as well as comprehensive clin-
ical phenotyping. Literature review identified 2 proteins, 52 single-nucleotide polymorphisms (SNPs) and 72 gene-expression 
biomarkers that had previously been proposed as predictors of Tumor Necrosis Factor (TNF) inhibitor response (ΔDAS28-CRP).  
RESULTS: From these published TNFi biomarkers we found that 2 protein, 2 SNP and 8 mRNA biomarkers could be replicated in 
the 59 TNF initiating patients. Combining these replicated biomarkers into a single signature we found that we could explain 
51% of the variation in ΔDAS28-CRP. This corresponds to a sensitivity of 0.73 and specificity of 0.78 for the prediction of three 
month ΔDAS28-CRP better than –1.2. CONCLUSIONS: The COMBINE biobank is currently the largest collection of multi-omics 
data from RA patients with high potential for discovery and replication. Taking advantage of this we surveyed the current 
state-of-the-art of drug-response stratification in RA, and identified a small set of previously published biomarkers available 
in peripheral blood which predicts clinical response to TNF blockade in this independent cohort.
online address: http://www.molmed.org
doi: 10.2119/molmed.2016.00078
*LK and LB contributed equally to this work.
Address correspondence to Lasse Folkersen. Center for Biological Sequence Analysis, 
Department of Bioinformatics, Technical University of Denmark, Building 208, 2800 Lyngby, 
Denmark. Phone: + 45-29936063; Fax: +45-45931585; E-mail: lasfol@cbs.dtu.dk. 
Submitted March 23, 2016; Accepted for publication June 24, 2016; Published Online 
(www.molmed.org) August 15, 2016.
R E S E A R C H  A R T I C L E
 M o l  M e D  2 2 : 3 2 2 - 3 2 8 ,  2 0 1 6  |  F o l k e r s e n  e T  A l .  |  3 2 3
sex as closely matched with patient 
groups as possible. The blood samples 
were collected at the baseline visit 
(timepoint 0m) and at a follow-up visit 
approximately 3 months later (time-
point 3 months, 95.3 d, standard deviation 
(SD) 10.5 in patient groups, but larger 
variation in healthy controls). At both 
visits patients underwent a full clinical 
evaluation, and data were recorded on 
number of swollen and tender joints, 
general health, C-reactive protein  
(CRP) and erythrocyte sedimentation 
rate (ESR). From these the disease ac-
tivity score (DAS28) was calculated, 
and we have specifically used the 
DAS28 including CRP levels in our 
analysis. At the clinical visits infor-
mation regarding smoking status, all 
the ACR 1987 or the 2010 ACR/EULAR 
criteria, who were undergoing change 
or start of a new treatment regimen at 
the Rheumatology Clinic, Karolinska 
University Hospital, Stockholm from 
February 2011 to May 2013. Our cohort 
includes 3 patients groups (Figure 1A): 
one group of patients with symptoms 
initiating no more than 14 months ago 
and initiating MTX treatment (cohort 
A), one group of early RA patients ini-
tiating anti-TNF therapy of any type 
(cohort B) and one group of patients 
initiating a second-line biologics treat-
ment, which could be either anti-TNF 
or other biologics (cohort C). Addition-
ally, healthy controls were recruited 
from the Swedish Blood Centre service 
in Uppsala (cohort HC), with age and 
fail to respond, upon which other bio-
logic therapies are prescribed. The cur-
rent challenge of translational research in 
this area is to better utilize the treatment 
options that already exist, in a personal-
ized or stratified manner. Several groups 
have attempted to use transcriptomics 
(3–10), genetics (11–13) and proteomics 
(14), as well as better use of clinical data 
(15) to predict treatment response, par-
ticularly for TNF blockade. Success has 
been limited with virtually no findings 
validated in independent material, and 
no biomarker for prediction of response 
is currently used in clinical practice 
(11). In any such study the collection of 
relevant biological samples is of key im-
portance, and independent validation of 
results is necessary for further research.
We therefore set out to compile the 
COMBINE biobank of samples from RA 
patients that included global profiling 
of transcriptomics, genetics, proteomics, 
flow cytometry and clinical information. 
With this unique resource, as a first stage 
we performed a complete quantification 
of all previously suggested anti-TNF 
response biomarkers: to investigate how 
well precision medicine would actually 
work, given the input of all previous 
knowledge on RA precision medicine 
that we have today. To our knowledge 
this biobank is currently the largest col-
lection of such multi-omics data from RA 
patients. We present this as an essential 
guidance in the highly discrepant field 
of drug response stratification research, 
as a resource for combining the findings 
of the many excellent studies already 
published.
MATerIAls AnD MeTHoDs
study Design and sample Collection
The COMBINE biobank was gen-
erated after written informed consent 
from all participants had been obtained 
according to the declaration of Helsinki 
and with approval by the Stockholm 
(number 2010-351-31-2) and Uppsala 
(2009-013) Regional Ethics Committees. 
The key inclusion criteria were patients 
with rheumatoid arthritis, according to 
Figure 1. A) Overview of study design and cohort setup. B) DAS28-CRP score stratified 
by cohort and visit time, with an assumed value of 0 for the HC cohort. Each dot shows 
one sample. The Y-axis shows DAS28-CRP level and the X-axis shows cohort membership 
and time point. Grey lines connect paired time-points, and horizontal black bars indicate 
 median value. Color-coding corresponds to figure 2C. C) Reproducibility of RNA-seq 
expression levels from technical replicates, in different library preparations with three 
months separation. Each dot shows the read count of one single gene. The Pearson 
correlation coefficent of log transformed counts was 0.991 (P<2e-16). D) Principal com-
ponents analysis of genome-wide genotype profile and self-reported country of origin of 
individuals. Each dot shows one patient, color-coded by self-reported country of origin. 
TNFi: TNF inhibitor, MTX: Methotrexate, Rx naïve: no methotrexate initation.
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 components instead being driven by 
smaller outliers or sex.
Imputation of non-measured SNPs 
was performed using the Mach1.0 im-
putation algorithm (1.0.18.c), with sep-
arate phasing in minimac (2012-11-16). 
For reference the 1,000 genomes project 
EUR was used (release_v3.20101123). 
This provided 7.7 million SNPs avail-
able for analysis at Rsq quality values 
above 0.7.
Association Between Biomarkers 
and DAs28-CrP
The primary outcome variable was 
defined as difference in DAS28-CRP three 
months after initiation of treatment with 
TNF inhibitors. To account for variance 
in methodology of the included dis-
covery studies, the association between 
biomarker level at baseline and ΔDAS28-
CRP was calculated using 4 different 
models: one model which used a Student 
t test between patients with ΔDAS28-CRP 
values above and below –1.2, and three 
linear regression models, one without co-
variates, one with age and sex as covari-
ate and one with age, sex and baseline 
DAS28-CRP value as covariate. One ex-
ception was the protein data in Figure 2C, 
which was handled using the same split 
by median values described in Dennis 
et al. (14). This was followed by a linear 
regression with the indicated four protein 
level categories as predictor variable.
The multiple testing burden of the 
study corresponds to the count of liter-
ature identified biomarker candidates. 
Details of the literature search are pro-
vided in Supplement 1. A total of 2 + 52 
+ 72 biomarkers were included in the re-
stricted search space. For these, P values 
are always reported as raw uncorrected 
values. The comparison plot in Figure 2B 
was made using the smooth Scatter from 
the R-graphics base-package and the 
receiver operated characteristics plot in 
Figure 2D was calculated using a ROCR 
package. All calculations were performed 
in R version 3.1.2.
All supplementary materials are available 
online at www.molmed.org.
and a check for Y-chromosome expres-
sion. Altogether 17 RNA samples were 
re-sequenced due to quality concerns 
and finally 2 samples were omitted from 
the study. A total of 360 samples were 
successfully RNA  sequenced. One of the 
samples was divided in two aliquots 
before library preparation to investigate 
reproducibility of RNA-sequence  
expression.
A pre-filtering on quality of reads 
using the fastqc package (0.10.1) was ap-
plied, removing adaptors and applying 
fastqc_quality_trimmer (-q 30, -p 85) 
and fastqc_quality_filter (-t 30 –L 40). 
This was followed by tophat2 (2.0.10) 
alignment to the ensemble GRCh37 
genome together with the –gtf switch 
with the hg19 UCSC transcripts (16). 
Gene expression was quantified using 
htseq followed by TMM-normalization, 
mean-scaling and log2 transformation 
as implemented in the edgeR package 
(3.8.6) (17) as recommended by Dillies 
et al. (18).
DnA Purification and Microarray 
Genotyping
Blood was collected in Vacutainer 
citrate tubes (BD) and DNA purified 
according to the QIAsymphony 400-ul 
buffy coat protocol. The DNA was hy-
bridized using the HumanOmniExpress 
BeadChip Kit and Illumina OmniEx-
press arrays (12v1). Y-chromosome call 
rates were compared with recorded sex 
and found to be mismatched for three 
samples which were excluded. Because 
of these sex concordance based sample 
switches, coding genotypes in highly ex-
pressed genes were compared with those 
obtained from RNA-sequence data using 
the allelicImbalance package (1.4.2) (19). 
This resulted in an additional 3 omitted 
samples due to mismatch of genotypes 
call. Altogether 230 individuals were 
successfully genotyped. Principal compo-
nents analysis was performed using the 
made4 package (1.40.0) on all measured 
genotypes. The first 10 principal com-
ponents were  investigated – the eighth 
and ninth showed the best resolution of 
larger ethnicity groups, the remaining 
current and previous medications, cell 
counts of all subsets of leukocytes, as 
well as samples for RNA sequencing 
of peripheral blood mononuclear cells 
(PBMC), flow cytometry analysis of 
PBMC and whole blood and serum and 
plasma analyses for protein biomarkers 
were taken. At baseline, patients were 
additionally evaluated for anticitrul-
linated protein antibody (ACPA) and 
rheumatoid factor (RF) positivity, and 
gave DNA samples for microarray ge-
notyping and human leukocyte antigen 
(HLA) haplotype characterization. A 
total of 492 blood samples from 246 dif-
ferent individuals were collected.
serum Protein Measurements
Proteins were measured using mul-
tiple commercial protein biomarker 
panels. These included 62 analytes in the 
HumanMAP assay (Myriad RBM), 12 
analytes in the VectraDA (Crescendo) as 
well as 33 autoantibodies using a fluores-
cence enzyme immunoassay technique 
from Phadia (Thermo Scientific). These 
plasma protein analyses were performed 
at external centers according to the stan-
dard protocols of the labs as indicated. 
The proteins BAFF and CXCL13 were 
analyzed using RnD Systems and APRIL 
using AH Diagnostics ELISA kits. De-
pending on assay type, between 422 and 
451 samples were successfully analyzed.
rnA Purification and sequencing
RNA was purified from PBMC samples 
collected using CPT tubes (BD Biosci-
ences) and purified using isopropanol 
extraction. The quality of each RNA sam-
ple was characterized using an Agilent 
Bioanalyser (2100 total RNA pico chip). 
RNA was sequenced at the Aros Applied 
Biotechnology center, using an Illumina 
HiSeq 2000, the TruSeq RNA sample 
preparation kit and 2 × 100 base pair (bp) 
paired end setup. Samples were random-
ized to flow cells with focus on obtaining 
balanced distribution of cohort type and 
drug response magnitude. Mean read 
depth was 15.7 million read-pairs per 
sample. Sample quality was inspected 
using read depth, fastqc quality calls 
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derived ethnicity of participants, which 
could be an important aspect of the like-
lihood of reproducing SNP-based drug 
stratification markers.
Transcriptomics-Based Anti-TnF-
response Association
Using keywords anti-TNF, RA and 
gene expression profiles in blood cells 
we  identified eight other studies contain-
ing similarly designed setups of gene 
expression profiles and data for anti-
TNF- response transcriptomics (3–10). 
For each of these studies we sought to 
replicate the findings in the COMBINE 
biobank (Figure 2A). From a total of 
72 candidates of previously proposed 
blood gene expression biomarkers, we 
observed that the genes SORBS3, AKAP9, 
CYP4F12, MUSTN (4), CX3CR1 (5), 
SLC2A3 (6), C21orf58 and TBC1D8 (7) 
could be replicated as stratification bio-
markers at P < 0.05 from the COMBINE 
dataset, and with consistent direction. 
One study had provided genome-wide 
expression data from whole blood, acces-
sion GSE33377 (10), and we additionally 
attempted to quantify how much overlap 
of findings there was when considering 
all genes (Figure 2B). Ideally one would 
expect several genes to have strong signif-
icance in both studies, which was not the 
case. There is thus a limited ability to re-
produce findings between cohorts of oth-
erwise similar size, which emphasizes the 
need for more validation studies in the 
field and argues for integration of data 
obtained from several patient cohorts.
Proteomics-Based Anti-TnF-response 
Association
Next, we performed a similar anal-
ysis for recent findings that sICAM1 
and CXCL13 serum protein levels 
could be used for stratification of anti-
TNF- response (14). When dividing the 
anti-TNF initiating patients (cohort B) 
into medians of sICAM1 and CXCL13 
levels and comparing the results of the 
four groups as done by Dennis et al., we 
found a strong replication of the original 
findings (Figure 2C). Interestingly, cor-
relation and other approaches that were 
Herein is also a clear illustration of the 
main issue of non-response to common 
drug types: only 47% of the patients had 
ΔDAS28-CRP scores better than –1.2 for 
evaluation at 3 months after treatment 
 initiation. Figure 1C shows the precision 
of the RNA-sequence and Figure 1D il-
lustrates the self-reported and genotype 
resUlTs
In the COMBINE biobank we col-
lected 492 blood samples from 246 
individuals, and applied a range of 
high-throughput measurement tech-
niques to most them (Table 1). The study 
design is illustrated in Figure 1A, and 
the DAS28-CRP changes in Figure 1B. 
Figure 2. A) Replication of mRNA as stratification biomarkers for anti-TNF-response in 
59 patients from cohort B. Each dot shows one gene, and the Y-axis shows associa-
tion strength. For each of 7 published studies, all reported genes were investigated for 
association to anti-TNF-response. Four different models were calculated: three linear 
regressions with different covariate setups, and one binary-response/no-response setup 
set at ΔDAS28-CRP < −1.2. The strongest covariates reported in the respective studies are 
indicated by the color code in the legend. B) Comparison with mRNA expression data 
from Toonen et al. (GSE33377). The X- and Y-axis shows the log10(P)-value for associa-
tion with TNFi response for each measured gene, from the Combine and the GSE33377 
data, respectively. The compared P-values were calculated based on binary response/
no-response. C) Replication of serum protein expression biomarkers sICAM1 and CXCL13 
previously reported by Dennis et al. (14). Protein levels were divided by median values for 
each of the two proteins as indicated along X-axis. The P-value was calculated for a lin-
ear regression over the four levels. Each dot shows one patient. Color coding and symbol 
shape indicate baseline DAS28-CRP and gender. D) ROC plot illustrating the ability to esti-
mate if a patient will have more or less than −1.2 ΔDAS28-CRP values, based on the fitted 
values of a model containing the 11 predictive biomarkers. This curve shows how different 
threshold levels will affect the rate of true and false positives predicted: the interpretation 
of the area under curve (AUC) is that 81.5% of randomly selected TNFi responders will 
have a higher test result than randomly selected non-responders.
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from GWAS literature (12,13). Combin-
ing these 11 variables gives a model that 
explains 51% of the variation in ΔDAS28-
CRP in the TNFi group of the COMBINE 
cohort (linear regression, adjusted R2). 
The largest explanatory power came from 
the sICAM1/CXCL13 finding as well as 
the two most significant measures of gene 
expression levels (CX3CR1 and SLC2A3). 
If the ΔDAS28-CRP is converted to a bi-
nary response with –1.2 as cutoff, a ROC-
curve based on the fitted values yields an 
AUC of 0.815 (Figure 2D). An overview 
of all response and model definitions is 
given in the Supplement 3. This includes 
a comparison with age– gender–smoking 
status as well as ACR good response 
definitions.
DIsCUssIon
The main finding in our study was in 
replication of 11 biomarkers for anti-TNF 
response in RA and in successful inte-
gration of these biomarkers in a single 
model with high predictive value.
SNPs were considered. Since the COM-
BINE database is more than 10 times 
smaller than current cohorts for genetic 
association studies, it is underpowered 
for a formal validation of these SNPs. 
Nonetheless we tested all 52 SNPs for 
association to ΔDAS28-CRP after treat-
ment with TNF-blocking agents for 3 
months. Only two SNP were found to be 
associated with ΔDAS28-CRP in COM-
BINE, one rs6028945 (13) (P = 0.047) and 
one rs7305646 (12) (P = 0.014).
Integration of known Biomarkers 
for Anti-TnF-response Prediction
To provide an integrative approach 
for prediction of anti-TNF treatment, 
we tested the prediction level obtain-
able when combining the best current 
high-throughput methodology and 
published findings replicated in the 
COMBINE cohort. In the test we in-
clude the expression of the 8 genes from 
transcriptomics literature, the sICAM1/
CXCL13 finding (14) and the two SNPs 
not based on the arbitrary median cutoffs 
did not provide any ability to stratify 
patient groups. The number of Toculi-
zumab treated patients in the cohort was 
too low to allow separate replication of 
the Toculizumab findings in Dennis et al.  
Using only the levels of these two pro-
teins to predict anti-TNF-response of 
ΔDAS28-CRP below –1.2, we obtained a 
Receiver Operating Characteristic (ROC)-
curve with an Area Under Curve (AUC) 
of 0.714.
Genetic Associations with 
Anti-TnF-response
We identified three published studies 
that identified SNPs associated with 
 anti-TNF-response (11–13), as well as 
the results from the winning algorithm 
at the recent Rheumatoid Arthritis 
Responder Challenge, developed by 
team GuanLab, University of Michigan 
(https://www.synapse.org/#!Syn-
apse:syn2504648). Altogether 52 po-
tentially anti-TNF- response associated 
Table 1. Demographic information for patients in the biobank.
HC-0m 
(n = 61)
HC-3m 
(n = 38)
A-0m  
(n = 92)
A-3m 
(n = 81)
B-0m 
(n = 59)
B-3m 
(n = 57)
C-0m 
(n = 34)
C-3m 
(n = 30)
Age (y) 47 ± 13 60 ± 15 55 ± 13 55 ± 15
Female 61% (37) 72% (66) 69% (41) 71% (24)
CPP-positive 60% (55) 78% (46) 79% (27)
RF-positive 54% (50) 66% (39) 76% (26)
DAS28-CRP 4.5 ± 1.2 2.8 ± 1.2 4.4 ± 1.2 3.2 ± 1.2 4.7 ± 1.2 3.4 ± 1.2
CRP (mg/mL) 14 ± 24 5.7 ± 15 11 ± 22 5.9 ± 14 12 ± 15 10 ± 14
ESR (mm) 32 ± 22 19 ± 14 20 ± 13 17 ± 13 28 ± 19 24 ± 15
Pain (VAS mm) 52 ± 27 22 ± 22 45 ± 26 30 ± 28 50 ± 22 42 ± 28
CD3 + T cells of PBMC (%) 60 ± 7.3 59 ± 7.5 51 ± 18 53 ± 14 49 ± 19 55 ± 13 55 ± 17 61 ± 8.4
CD19 + B cells of PBMC (%) 7.7 ± 2.7 7.6 ± 2.5 7.4 ± 4.4 8.4 ± 5 6.4 ± 3.8 7.5 ± 3.6 6.7 ± 4.1 4 ± 4.4
CD3-CD56 + NK cells of 
PBMC (%)
10 ± 4.6 10 ± 4.7 8.4 ± 5.1 9.2 ± 5 7.8 ± 4.2 8.7 ± 4.7 8.6 ± 5.2 8.6 ± 5
CD14 + Monocytes of 
PBMC (%)
17 ± 4.5 18 ± 6.1 18 ± 8.5 20 ± 8.3 18 ± 11 19 ± 10 19 ± 8.3 20 ± 7.9
Has RNA-seq 97% (59) 52% (32) 74% (68) 65% (60) 75% (44) 80% (47) 74% (25) 74% (25)
Has genotyping 93% (57) 93% (57) 95% (87) 95% (87) 93% (55) 93% (55) 91% (31) 91% (31)
CCP: cyclic citrullinated peptide, CRP: C-reactive protein, RF: rheumatic factor, DAS28-CRP: disease activity score 28, ESR: erythrocyte 
sedimentation rate, PBMC: peripheral blood mononuclear cells, RF: rheumatic factor, VAS: visual analog scale.
Numerical variables are reported as mean ± SD and categorical variables are reported as percentage (count).
Cohort HC: healthy controls.
Cohort A: treatment naïve, initiating Methotrexate.
Cohort B: methotrexate non-responders, initiating TNFi.
Cohort C: TNFi non-responders, initiating second biological (Supplementary Figure S2).
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